<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ911206-0045</DOCNO><DOCID>911206-0045.</DOCID><HL>   Business Brief -- Amgen Inc.:   Firm Wins Patent Dispute   With Genetics Institute Inc.</HL><DATE>12/06/91</DATE><SO>WALL STREET JOURNAL (J), PAGE A4</SO><CO>   AMGN GENI</CO><MS>CONSUMER NON-CYCLICAL (NCY)TECHNOLOGY (TEC)</MS><IN>BIOTECHNOLOGY (BTC)DRUG MANUFACTURERS (DRG)MEDICAL andamp; BIOTECHNOLOGY, GENETIC RESEARCH, PROSTHETICS (MTC)</IN><NS>PATENTS (PAT)</NS><GV>COMMERCE DEPARTMENT (COM)</GV><RE>CALIFORNIA (CA)MASSACHUSETTS (MA)NORTH AMERICA (NME)PACIFIC RIM (PRM)UNITED STATES (US)</RE><LP>   The U.S. Patent Office ruled in favor of Amgen Inc. andagainst Genetics Institute Inc. in a dispute involving threepatents for an anti-anemia drug, Amgen said.   The decision further strengthens Amgen's patent rights tothe drug, erythropoietin, that were upheld by other courtrulings this year. One of the disputed patents was awardedseveral years ago, and the Thousand Oaks, Calif.,biotechnology company expects the other two to be issuedsoon.</LP><TEXT>   A spokeswoman for Genetics Institute, a Cambridge, Mass.,biotechnology concern, said she couldn't comment because thecompany hadn't seen a copy of the Patent Office decision.</TEXT></DOC>